Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 1826

1.

Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells.

Xu L, Xie Q, Qi L, Wang C, Xu N, Liu W, Yu Y, Li S, Xu Y.

Oncol Rep. 2018 Mar;39(3):985-992. doi: 10.3892/or.2017.6164. Epub 2017 Dec 19.

2.

Association of BCL-2 with oxidative stress and total antioxidant status in pediatric acute lymphoblastic leukemia.

Tahir IM, Iqbal T, Jamil A, Saqib M.

J Biol Regul Homeost Agents. 2017 Oct-Dec;31(4):1023-1027.

PMID:
29254309
3.

DNA structural basis for fragility at peak III of BCL2 major breakpoint region associated with t(14;18) translocation.

Javadekar SM, Yadav R, Raghavan SC.

Biochim Biophys Acta Gen Subj. 2018 Mar;1862(3):649-659. doi: 10.1016/j.bbagen.2017.12.003. Epub 2017 Dec 12.

PMID:
29246583
4.

TAT‑fused IP3R‑derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca2+ release.

Xie Q, Xu Y, Gao W, Zhang Y, Su J, Liu Y, Guo Y, Dou M, Hu K, Sun L.

Int J Mol Med. 2018 Feb;41(2):809-817. doi: 10.3892/ijmm.2017.3260. Epub 2017 Nov 16.

5.

A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.

Monaco G, La Rovere R, Karamanou S, Welkenhuyzen K, Ivanova H, Vandermarliere E, Di Martile M, Del Bufalo D, De Smedt H, Parys JB, Economou A, Bultynck G.

FEBS J. 2018 Jan;285(1):127-145. doi: 10.1111/febs.14324. Epub 2017 Dec 2.

PMID:
29131545
6.

Therapeutics targeting Bcl-2 in hematological malignancies.

Ruefli-Brasse A, Reed JC.

Biochem J. 2017 Oct 23;474(21):3643-3657. doi: 10.1042/BCJ20170080. Review.

PMID:
29061914
7.

Induction of the chromosomal translocation t(14;18) by targeting the BCL-2 locus with specific binding I-125-labeled triplex-forming oligonucleotides.

Dahmen V, Schmitz S, Kriehuber R.

Mutat Res. 2017 Nov;823:58-64. doi: 10.1016/j.mrgentox.2017.09.002. Epub 2017 Sep 14.

PMID:
28985947
8.

Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.

Cyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M.

Blood. 2017 Nov 9;130(19):2073-2083. doi: 10.1182/blood-2017-06-792150. Epub 2017 Oct 2.

9.

Effects of genomic disruption of a guanine quadruplex in the 5' UTR of the Bcl-2 mRNA in melanoma cells.

Serikawa T, Eberle J, Kurreck J.

FEBS Lett. 2017 Nov;591(21):3649-3659. doi: 10.1002/1873-3468.12855. Epub 2017 Oct 3.

10.

A study of the distribution of B-cell lymphoma/leukemia-2 in odontogenic cyst and tumors: Histochemical study.

Phull K, Metgud R, Patel S.

J Cancer Res Ther. 2017 Jul-Sep;13(3):570-575. doi: 10.4103/0973-1482.183197.

11.

Interaction of the N-Terminal Tandem Domains of hnRNP LL with the BCL2 Promoter i-Motif DNA Sequence.

Lannes L, Young P, Richter C, Morgner N, Schwalbe H.

Chembiochem. 2017 Oct 18;18(20):2033-2044. doi: 10.1002/cbic.201700390. Epub 2017 Sep 8.

PMID:
28805284
12.

Bcl-2 antigen expression in luminal A and triple-negative breast cancer.

Escórcio-Dourado CS, Martins LM, Simplício-Revoredo CM, Sampaio FA, Tavares CB, da Silva-Sampaio JP, Borges US, Alves-Ribeiro FA, Lopes-Costa PV, Lima-Dourado JC, da Silva BB.

Med Oncol. 2017 Aug 11;34(9):161. doi: 10.1007/s12032-017-1022-2.

PMID:
28801774
13.

High expression of anti-apoptotic protein Bcl-2 is a good prognostic factor in colorectal cancer: Result of a meta-analysis.

Huang Q, Li S, Cheng P, Deng M, He X, Wang Z, Yang CH, Zhao XY, Huang J.

World J Gastroenterol. 2017 Jul 21;23(27):5018-5033. doi: 10.3748/wjg.v23.i27.5018. Review.

14.

Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.

Ozretic P, Alvir I, Sarcevic B, Vujaskovic Z, Rendic-Miocevic Z, Roguljic A, Beketic-Oreskovic L.

Int J Biol Markers. 2018 Jan;33(1):109-115. doi: 10.5301/ijbm.5000291.

PMID:
28777433
15.

BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database.

Hwang KT, Kim K, Chang JH, Oh S, Kim YA, Lee JY, Jung SH, Choi IS.

Cancer Res Treat. 2018 Jul;50(3):658-669. doi: 10.4143/crt.2017.134. Epub 2017 Jul 4.

16.

BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.

Tsuyama N, Sakata S, Baba S, Mishima Y, Nishimura N, Ueda K, Yokoyama M, Terui Y, Hatake K, Kitagawa M, Ishizuka N, Tomita N, Takeuchi K.

Blood. 2017 Jul 27;130(4):489-500. doi: 10.1182/blood-2016-12-759621. Epub 2017 May 18.

17.

Two Distinct BCL2 Rearrangements, Each Observed in 2 Independent Subclones, Evolving from a Founder Clone with Trisomy 12 in a Unique Case of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Peterson JF, Shah R, Kobrinski D.

Acta Haematol. 2017;137(4):237-239. doi: 10.1159/000474926. Epub 2017 May 18. No abstract available.

PMID:
28514780
18.

Genetic polymorphisms of Bcl-2 promoter in cancer susceptibility and prognosis: a meta-analysis.

Yao Z, Yang B, Liu Z, Li W, He Q, Peng X.

Oncotarget. 2017 Apr 11;8(15):25270-25278. doi: 10.18632/oncotarget.15751.

19.

Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder.

Hess J, Stelmach P, Eisenhardt A, Rübben H, Reis H, Schmid KW, Bachmann HS.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1659-1670. doi: 10.1007/s00432-017-2404-8. Epub 2017 Apr 17.

PMID:
28417194
20.

BCL2 genotypes and prostate cancer survival.

Renner W, Langsenlehner U, Krenn-Pilko S, Eder P, Langsenlehner T.

Strahlenther Onkol. 2017 Jun;193(6):466-471. doi: 10.1007/s00066-017-1126-9. Epub 2017 Apr 10.

Supplemental Content

Support Center